mexico update, page-65

got my answer to my last question:

(a) the payment of amounts owing in relation to the Company’s acquisition of SBL;
(b) the commercialisation of the Chinese joint venture with SiYi, including the capital
expenditure required to increase the production capacity at the existing plant to
accommodate a higher volume of sales;
(c) the development of the BioScreens Cup and the cost of attaining FDA 510(k)
Clearance for point-of-care sale of the VisuaLine product;
(d) the development and marketing of OraLine VIII;
(e) developing SBL’s compliance with Good Manufacturing Practices; and
(f) working capital to support the ongoing business activities of the Company.